Latest Shareholder Approvals News

Morella Corporation has raised A$2.1 million through a placement to fund drilling at its Mt Edon Rubidium–Lithium Project, marking a key step toward defining a maiden mineral resource estimate.

Westar Resources is set to raise $1.49 million through a two-tranche share placement aimed at funding exploration and new project due diligence. The placement features discounted share prices and awaits shareholder approval for the larger second tranche.

Tartana Minerals is advancing its strategic metals portfolio in Far North Queensland with a robust 2026 drilling program and ongoing copper sulphate production, aiming to unlock significant resource potential across silver, gold, and copper assets.

Celsius Resources has raised A$9.3 million through a well-supported institutional placement, strengthening its balance sheet to advance the financing and early development of its flagship MCB copper-gold project in the Philippines.

Pantoro Gold has announced a significant on-market share buy-back of up to 10% of its shares, leveraging strong cashflow from its Norseman Gold Project to enhance shareholder value while funding growth.

Pharmx Technologies has entered a multi-year strategic alliance with Sigma Healthcare, becoming the preferred EDI provider for Sigma and Chemist Warehouse across Australia and New Zealand, while Sigma takes a significant equity stake.

Hartshead Resources has updated the schedule for its proposed acquisition by ACAM GP Limited, with key shareholder and court dates set through May 2026. The revised timetable outlines the next steps in the scheme of arrangement process.

Multistack International Limited posted a surprising $2.26 million net profit for 2025, driven by one-off settlement income, while its core operations continue to falter, prompting plans to exit its current business model.

Kuniko Limited has raised A$3.75 million in a strongly supported placement to fast-track drilling and resource expansion at its Commonwealth Gold–Silver Project in NSW’s Lachlan Fold Belt. Phase I drilling is underway, with results expected in April 2026.

Murray Cod Australia has appointed Steven Chaur as its new Managing Director and CEO, aiming to accelerate revenue growth and operational efficiency from April 2026. The move signals a strategic push to deepen domestic channels and expand the luxury fish brand’s market presence.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Ramsay Health Care is set to simplify its corporate structure by distributing its majority stake in European healthcare provider Ramsay Santé directly to shareholders, enabling focused growth strategies for both entities.